Dyslipidemia management in diabetes

ConclusionsSeveral existing and newer drug treatments reduce ASCVD risk through LDL cholesterol and/or triglyceride reduction in patients with diabetes. Novel approaches using antisense oligonucleotides and monoclonal antibodies may provide potential future therapies for diabetic dyslipidemia.
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research